Financials in USD. Standardized financial statements.
A compact view of how Akoya Biosciences, Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue? | $81.67M | $96.63M | $74.86M | $54.92M | $42.44M | $42.24M |
| Revenue Growth? | -15.5% | +29.1% | +36.3% | +29.4% | +0.5% | 0.0% |
| Cost of Revenue? | $33.79M | $40.33M | $31.47M | $20.70M | $16.54M | $17.57M |
| Gross Profit? | $47.88M | $56.30M | $43.39M | $34.22M | $25.91M | $24.66M |
| Gross Margin? | +58.6% | +58.3% | +58.0% | +62.3% | +61.0% | +58.4% |
| Operating Expenses? | $94.61M | $113.97M | $109.60M | $71.44M | $37.40M | $38.17M |
| Operating Income? | -$46.73M | -$57.67M | -$66.21M | -$37.23M | -$11.49M | -$13.50M |
| EBITDA? | -$37.14M | -$45.63M | -$58.81M | -$35.17M | -$10.13M | -$9.62M |
| Income Before Tax | -$55.22M | -$63.28M | -$70.52M | -$43.08M | -$16.66M | -$14.56M |
| Income Tax Expense | $146,000 | $40,000 | $123,000 | -$140,000 | $42,000 | $194,000 |
| Net Income? | -$55.37M | -$63.32M | -$70.64M | -$42.94M | -$16.71M | -$14.75M |
| EPS? | $-1.12 | $-1.43 | $-1.87 | $-1.19 | $-0.45 | $-0.40 |
| Diluted EPS? | $-1.12 | $-1.43 | $-1.87 | $-1.19 | $-0.45 | $-0.40 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality